# Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

> **NCT03691727** · PHASE1,PHASE2 · COMPLETED · sponsor: **David Hasan** · enrollment: 30 (actual)

## Conditions studied

- Subarachnoid Hemorrhage, Aneurysmal

## Interventions

- **DRUG:** tirofiban hydrochloride (AGGRASTAT®)
- **DIAGNOSTIC_TEST:** MRI
- **DIAGNOSTIC_TEST:** Neurological Exam
- **BEHAVIORAL:** Questionnaires
- **DIAGNOSTIC_TEST:** Vital Signs
- **OTHER:** Standard of Care Treatment

## Key facts

- **NCT ID:** NCT03691727
- **Lead sponsor:** David Hasan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-24
- **Primary completion:** 2020-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691727, "Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03691727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*